Breaking News

You are here » Indian-Commodity  :  Commodities  :  Turmeric  :  Turmeric futures edge higher on NCDEX

11-Apr2018

Turmeric futures edge higher on NCDEX

Turmeric futures edged higher on NCDEX due to rising domestic demand in the spot market. Although, some gains were capped due to arrival of new season crop and lower export demand.

The contract for April delivery was trading at Rs 6432 .00, up by 0.03 % or Rs 2.00 from its previous closing of Rs 6430.00. The open interest of the contract stood at 2215 lots.

The contract for May delivery was trading at Rs 6528 .00, rose by 0.09 % or Rs 6.00 from its previous closing of Rs 6522.00. The open interest of the contract stood at 12745 lots on NCDEX.






Related News

View all news

Turmeric futures trade higher on pick up in demand

Turmeric futures traded higher on NCDEX, in line with fresh buying at lower price levels amid anticipations on pick up in demand from domestic markets. However, reports on improved sowing in turmeric growing......

Turmeric futures trade higher on rise in demand

Turmeric futures traded higher on NCDEX, due to enlargement of position by speculators. Moreover, rise in demand from domestic spot markets also fuelled the uptrend.The contract for October delivery was......

Turmeric futures decline on higher arrivals

Turmeric futures traded lower on NCDEX, with the liquidation of bets tracking higher arrivals and improved sowing in turmeric growing areas of Tamilnadu, Karnataka and Maharashtra. Moreover, subdued demand......

Top News

View all news

Bhansali Engineering Polymers reports 33% fall in Q2 net profit

Bhansali Engineering Polymers has reported results for second quarter ended September 30, 2018.The company has reported 32.71% fall in its net profit at Rs 16.89 crore for the quarter under review as compared......

Biocon, Mylan N.V. receive positive CHMP opinion for Ogivri

Biocon and Mylan N.V. have announced that the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion recommending approval of Ogivri, a biosimilar......

Lupin Neurosciences receives positive CHMP opinion for NaMuscla

Lupin Neurosciences, a specialty pharma division of Lupin has announced that the Committee for Medicinal Products for Human Use (CHMP), the scientific committee of the European Medicines Agency (EMA),......